Legend Biotech Corporation P/E LTM
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| P/E LTM | (12.6x) | (20.5x) | (19.4x) | (21.5x) |
Legend Biotech Corporation (LEGN) P/E LTM comparison analysis
General
LTM P/E LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
LEGN key stats
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 23.6 0.0% | 49.1 108.2% | 57.3 16.5% | 75.7 32.2% | 89.8 18.7% | 117.0 30.3% | 285.1 143.7% |
| Cost of Goods Sold (COGS) | (0.1) | 0.0 | 0.0 | 232.2 | 313.3 | 65.4 | 144.2 |
% margin | 23.7 100.4% | 49.1 100.0% | 57.3 100.0% | (156.5) (206.8%) | (223.6) (249.0%) | 51.6 44.1% | 140.9 49.4% |
| Operating Expenses | 9.6 | 64.2 | 192.6 | 304.9 | 462.8 | 509.7 | 140.9 |
| Research & Development Expenses (R&D) | 8.2 | 60.6 | 161.9 | 232.2 | 313.3 | 335.6 | 382.2 |
| Selling, General & Administrative Expenses (SG&A) | 1.4 | 3.9 | 32.4 | 72.7 | 149.5 | 174.0 | 200.9 |
% margin | 13.8 58.4% | (1.5) (3.1%) | (130.9) (228.5%) | (313.3) (414.1%) | (393.0) (437.7%) | (455.8) (389.6%) | (439.5) (154.1%) |
| Interest Income | 0.0 | 6.2 | 4.6 | 2.9 | 1.0 | 8.2 | 54.5 |
| Interest Expense | 0.0 | 0.1 | 0.2 | 4.2 | 0.9 | 10.8 | 21.8 |
| Pre-tax Income | 13.8 | (1.6) | (130.4) | (307.6) | (386.2) | (445.7) | (520.1) |
% effective tax rate | 4.5 32.3% | 1.2 (72.3%) | 2.6 (2.0%) | (4.1) 1.3% | 0.0 (0.0%) | 0.6 (0.1%) | (1.9) 0.4% |
% margin | 9.4 39.7% | (2.8) (5.7%) | (133.0) (232.2%) | (303.5) (401.0%) | (386.2) (430.1%) | (446.3) (381.5%) | (518.3) (181.8%) |
| EPS | 0.07 | (0.03) | (1.01) | (2.57) | (2.74) | (2.81) | (2.94) |
| Diluted EPS | 0.07 | (0.03) | (1.01) | (2.57) | (2.74) | (2.81) | (2.94) |
% margin | 14.1 59.6% | 0.1 0.3% | (124.9) (218.1%) | (294.1) (388.7%) | (392.4) (437.0%) | (416.5) (356.0%) | (477.9) (167.6%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Legend Biotech Corporation's P/E LTM?
As of today, Microsoft Corp's last 12-month P/E LTM is (31.6x), based on the financial report for Sep 27, 2024 (Q3’2024). The average annual P/E LTM for Legend Biotech Corporation have been (20.9x) over the past three years, and (18.4x) over the past five years.
2) Is Legend Biotech Corporation's P/E LTM Good?
As of today, Legend Biotech Corporation's P/E LTM is (31.6x), which is lower than industry median of (1.5x). It indicates that Legend Biotech Corporation's P/E LTM is Good.